Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin

BACKGROUND: The high price is a critical barrier of access to new direct-anting-antiviral (DAA) therapies for hepatitis C for both the patients and the society. Many countries continue to face the challenge of financing such expensive medicines. Such examples include both high-income and middle-inco...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peiwen, Guo, Ran, Lian, Jun, Zhi, Mengjia, Lu, Chengzhen, Wu, Weishen, Wang, Lihong, Chan, Polin, Chen, Zhongdan, Sun, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181951/
https://www.ncbi.nlm.nih.gov/pubmed/32346522
http://dx.doi.org/10.5334/aogh.2763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181951/
https://www.ncbi.nlm.nih.gov/pubmed/32346522
http://dx.doi.org/10.5334/aogh.2763

Ejemplares similares